Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 34-year-old woman is evaluated in the rheumatology clinic for a follow-up visit. She was diagnosed with severe rheumatoid arthritis 2 years ago and has been managed with weekly oral methotrexate and daily folic acid. Over the past three months, she has experienced worsening morning stiffness lasting up to 2 hours and increasing pain in her wrists and hands. Physical examination reveals active, boggy synovitis in the bilateral metacarpophalangeal and proximal interphalangeal joints. She has no significant past medical history other than rheumatoid arthritis, and a comprehensive review of systems is negative. Her vital signs are within normal limits. Recent laboratory studies show a hemoglobin of 11.4 g/dL, an aspartate aminotransferase of 36 U/L (normal: 8-40 U/L), and an alanine aminotransferase of 44 U/L (normal: 7-35 U/L). Given the inadequate response to her current regimen, the physician plans to add etanercept to her treatment. Before starting this new medication, which of the following screening tests are required? (Select all that apply)

  1. Interferon-gamma release assayAnswer
  2. Hepatitis B surface antigen and core antibodyAnswer
  3. C
    Percutaneous liver biopsy
  4. D
    Transthoracic echocardiogram
  5. E
    Thiopurine methyltransferase activity level

Answer

The required screening tests are an interferon-gamma release assay and Hepatitis B surface antigen and core antibody.
Tumor necrosis factor (TNF) alpha inhibitors, such as etanercept, infliximab, and adalimumab, are highly effective biologic agents for severe rheumatoid arthritis. However, TNF-alpha plays a critical role in the formation and maintenance of granulomas and in the control of viral replication. Therefore, these medications significantly increase the risk of reactivating latent granulomatous diseases (most notably tuberculosis) and viral hepatitis. Standard clinical guidelines strictly require that all patients undergo screening for latent tuberculosis (using an interferon-gamma release assay or a tuberculin skin test) and Hepatitis B (using surface antigen and core antibody) before starting therapy. If a patient tests positive for either latent condition, appropriate prophylactic or antiviral therapy must be instituted before the biologic agent can be safely administered.

Step-by-Step Solution

1
Identify the planned pharmacologic intervention and the underlying disease condition.
The patient has active rheumatoid arthritis and is planned to start etanercept, a tumor necrosis factor (TNF) alpha inhibitor.
Different classes of disease-modifying antirheumatic drugs (DMARDs) and biologic therapies have distinct baseline monitoring and screening requirements based on their adverse effect profiles.
2
Determine the specific immunological risks associated with the chosen medication.
TNF-alpha inhibitors suppress the cell-mediated immune response, which is crucial for maintaining granulomas and suppressing viral replication.
Loss of this immune surveillance can lead to the catastrophic reactivation of latent infections.
3
Select the appropriate baseline laboratory parameters required by clinical guidelines.
Guidelines mandate screening for latent tuberculosis and Hepatitis B prior to the initiation of any TNF-alpha inhibitor.
Identifying and prophylactically treating latent tuberculosis and Hepatitis B prevents life-threatening disseminated disease or fulminant hepatitis.

Key Concept

Baseline monitoring and screening for latent infections (Tuberculosis and Hepatitis B) prior to initiating TNF-alpha inhibitors.
Estimated Time:1m 15s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic